Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

EMCURE PHARMACEUTICALS LTD.

NSE : EMCUREBSE : 544210ISIN CODE : INE168P01015Industry : Pharmaceuticals & DrugsHouse : Private

BSE1425.10-0.3 (-0.02 %)

PREV CLOSE ( ) 1425.40

OPEN PRICE ( ) 1425.40

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 16990

TODAY'S LOW / HIGH ( )1403.05 1455.00

52 WK LOW / HIGH ( )890 1577.5

NSE1425.20-0.5 (-0.04 %)

PREV CLOSE( ) 1425.70

OPEN PRICE ( ) 1425.70

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1425.20 (893)

VOLUME 215470

TODAY'S LOW / HIGH( ) 1402.60 1458.00

52 WK LOW / HIGH ( )889 1580

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 16-04 1981

Management Info

Berjis Minoo Desai - Chairman Satish Ramanlal Mehta - Managing Director

Registered Office

Address Plot No. P-1 & P-2,I T - B T Park, Phase- I I,M I D C, Hinjawadi,
Pune,
Maharashtra-411057

Phone 020-3507003 / 35070000

Email investors@emcure.com

Website www.emcure.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

17Jul Emcure Pharmaceuticals enters into agr
Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) have entered into..

17Jul Emcure Pharmaceuticals gains on enteri
Emcure Pharmaceuticals is currently trading at Rs. 1374.70, up by 10.85..

10Jul USFDA concludes PAI at Emcure Pharmace
United States Food and Drug Administration (USFDA) has concluded Pre-App..

04Jul Emcure Pharmaceuticals incorporates wh
Emcure Pharmaceuticals has incorporated a wholly-owned subsidiary (WOS)..

04Jul Emcure Pharmaceuticals informs about i
With reference to its disclosure dated June 21, 2025 (copy attached), pu..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	1395.57	3171.28
Gross Profit	1860.52	4277.1
Operating Profit	2670.33	7656.44
Net Sales	12781.88	43819.24

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 34745.50 (1.62%)	M.Cap ( in Cr)73831.76
Gland Pharma (BSE) 2031.00 (3.61%)	M.Cap ( in Cr)33462.03
Onesource Specialty (BSE) 2010.00 (3.13%)	M.Cap ( in Cr)23007.67
Procter&Gamble Healt (BSE) 5920.55 (1.00%)	M.Cap ( in Cr)9827.75
Concord Biotech (BSE) 1951.00 (2.83%)	M.Cap ( in Cr)20410.62

Shareholding Pattern

	PROMOTERS	77.91%
	NON-INSTITUTION	16.39%
	MUTUAL FUNDS/UTI	2.34%
	FI/BANKS/INSURANCE	0.24%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Bajaj Finserv Healt...	3.19
Aditya Birla SL Pha...	2.74
WOC Pharma and Heal...	1.99
DSP Healthcare Fund...	1.45
Edelweiss Recently ...	1.32
Aditya Birla SL Bal...	1.12
Aditya Birla SL Ret...	1.02

Risk Disclosures on Derivatives

Smart Quotes

EMCURE PHARMACEUTICALS LTD.